Published 5 months ago

FDA approves Onyda XR extended-release liquid nonstimulant ADHD drug

Summary by Healio

The FDA has approved Onyda XR extended-release oral suspension for the treatment of ADHD among children aged 6 years and older, according to a press release from Tris Pharma, Inc.Onyda XR (clonidine hydrochloride, Tris Pharma) is the first and only liquid nonstimulant ADHD medication in the United States and the only approved nonstimulant ADHD drug with nighttime dosing, according to the release.

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Stories disproportionately reported by the Left or the Right

Coverage Details

Total News Sources0

Leaning Left0Leaning Right0Center0Last Updated5 months agoBias Distribution

No sources with tracked biases.

Bias Distribution

There is no tracked Bias information for the sources covering this story.

Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Sources are mostly out of (0)

FDA approves Onyda XR extended-release liquid nonstimulant ADHD drug

Coverage Details

Bias Distribution

Ownership

Similar News Topics

Similar News Topics